Synopsis: Caplin Point Laboratories stands out among mid-sized pharma companies due to its diversified dosage portfolio, strong presence in complex sterile injectables, and strategic expansion into oncology and GLP-1 segments. With specialised manufacturing platforms and high regulatory compliance, it competes in high-barrier spaces while maintaining consistent growth and market outperformance.
Caplin Point Laboratories Ltd has emerged as a differentiated player in the pharmaceutical space, blending scale with specialisation. While positioned as a mid-sized company, it has built capabilities across multiple dosage forms, including complex sterile injectables and speciality products. Its growing footprint in regulated markets, focus on high-entry-barrier segments, and structured manufacturing expansion strategy set it apart from conventional generic-focused peers.
With a market cap of Rs 12,933 crore, the shares of Caplin Point Laboratories Ltd have closed at Rs 1,701 and are trading at a PE of 21.1 compared to its industry PE of 27.9. The shares have given a return of about 250% in the last 5 years.
What does the company do?
Caplin Point Laboratories Limited is a completely integrated pharmaceutical company that deals with the manufacturing, development, and distribution of a broad spectrum of generic drugs. The company is focused on ointments, creams, and other topical preparations, besides developing various dosage forms for the global market. It operates with a strong presence in Latin America, the Caribbean, Francophone, and Southern Africa, primarily targeting the emerging markets.
With more than 4,000 product licences across the globe, it pursues a distinct business model that involves the ownership and operation of its own distribution channels, enabling it to serve the underserved and the bottom-of-the-pyramid population directly.
The company also has an expanding presence in the regulated markets of the United States and Europe. Its manufacturing plant has been inspected on multiple occasions by the US FDA and has received Establishment Inspection Reports (EIR) every time, indicating high compliance standards. Caplin has submitted multiple ANDAs to the US market and has approvals from international regulatory authorities such as EU-GMP, ANVISA (Brazil), INVIMA (Colombia), and COFEPRIS (Mexico).
Alongside its manufacturing strength, the company invests significantly in research and development to create safe, effective, and affordable pharmaceutical products across diverse therapeutic categories.
What makes Caplin Point stand out?
Caplin Point Laboratories Limited is unique in its category because of the broad range of dosage forms it has under one umbrella. In the emerging markets, it has large-scale capacities like 1500 Mn tablets, 400 Mn capsules, 220 Mn softgels, and syrups, sachets, suppositories, topicals, and injectables. In the regulated markets, it has the capacity to manufacture liquid & lyophilised vials and pre-filled syringes, which are more technologically advanced sterile forms.
The mid-sized pharma companies usually have their focus on either oral solids or a small range of injectables. Caplin, on the other hand, has its presence in oral solids, liquid orals, sterile injectables, ophthalmics, oncology products, and now APIs too. With 650+ formulations in 36 therapeutic areas, it has a unique portfolio depth, which is rare in companies of this size.
Focus on Complex & Niche Segments
Caplin’s move into complex sterile injectables and specialty platforms makes it distinct from commoditised generic companies. It has development platforms in lyophilised injectables, suspension injectables, emulsion injectables, pre-filled syringes (robotic line), ready-to-use IV bags, and niche ophthalmic products. These segments have much higher regulatory, technology, and capital hurdles, thus restricting competition.
With 55 approved ANDAs in the US (including partners) and forays into oncology injectables and GLP-1 products. Caplin is carving out a space in sectors where fewer mid-cap Indian companies are present. Though most competitors are under pricing pressure in oral generics, Caplin’s product base is gradually shifting towards sectors where technical know-how and regulatory requirements are more important than price.
What sets Caplin apart is the fact that it has created a multi-location, segment-specialised manufacturing network in a mid-sized company. It has dedicated manufacturing sites for sterile injectables, oncology formulations, oncology APIs, oral solids, and general APIs, with current expansion projects including new injectable and ophthalmic lines (COL-II) and oncology API facilities.
While most of its competitors are expanding incrementally in the same therapeutic or dosage form area, Caplin is developing platforms for future growth segments such as oncology, GLP-1, sterile ophthalmics, blow-fill-seal technology, and backward integration APIs. This makes it a unique case where a company is not only large in terms of product offerings but also has a segment-specialised structure in high-barrier, future-proof pharmaceutical areas.
The revenue from operations for the company stood at Rs 543 crores in Q3 FY26 compared to Q3 FY25 revenue of Rs 493 crores, up by about 10 per cent YoY. Similarly, the net profit stood at Rs 166 crore in Q3 FY26, up compared to the Rs 140 crore profit in Q3 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
